GLPwatch
Ozempic for Parkinson's disease
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCOzempic (semaglutide) is not FDA-approved for Parkinson's disease, and any use for this condition is off-label or investigational. Research in animal models suggests potential neuroprotective effects and reductions in α-synuclein levels, but these findings have not been confirmed in human clinical trials.
AI summary of the sources below.
| Drug | Ozempic (semaglutide) |
|---|---|
| Condition | Parkinson's disease |
| Approval status | Investigational / off-label |
| Research papers | 11 |
Ozempic is not FDA-approved for parkinson's disease; the research below reflects investigational or off-label study only.
Research on semaglutide for parkinson's disease (11)
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease.
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model.
- Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide.
- DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.
- Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress.
- The GLP1R Agonist Semaglutide Inhibits Reactive Astrocytes and Enhances the Efficacy of Neural Stem Cell Transplantation Therapy in Parkinson's Disease Mice.
- Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.
- Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.